Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3938577 in Healthy Participants and T2DM
NCT06132126Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3938577 in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Adverse Events at 44 days, Incidence of Hypoglycemia at 44 days and 2 more. Started Nov 2023; status: completed.
02
Drugs
LY3938577
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06132126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132126.